Relapses and serious adverse events during rituximab maintenance therapy in ANCA-associated vasculitis: a multicentre retrospective study.
Chrysoula G GialouriAglaia ChalkiaChristos KoutsianasKaterina ChavatzaEvangelia ArgyriouAlexandros PanagiotopoulosAnastasios KarmanakosAikaterini DimouliChristina TsalapakiKonstantinos ThomasPhilippos OrfanosPagona LagiouGeorge KatsikasKyriaki BokiDimitrios T BoumpasDimitrios PetrasDimitrios VassilopoulosPublished in: Rheumatology (Oxford, England) (2024)
In this real-world study, relapses during RTX-maintenance occurred in approximately in 1 out of 4 patients. Kidney involvement, induction with RTX plus cyclophosphamide and earlier achievement of complete-remission were associated with lower relapse-risk. Serious-infections rate was consistent with previous reports, whereas an increased rate of COVID19-associated hospitalizations was observed.
Keyphrases
- end stage renal disease
- ejection fraction
- coronavirus disease
- newly diagnosed
- sars cov
- chronic kidney disease
- clinical trial
- prognostic factors
- peritoneal dialysis
- diffuse large b cell lymphoma
- randomized controlled trial
- study protocol
- mesenchymal stem cells
- disease activity
- bone marrow
- double blind
- respiratory syndrome coronavirus
- replacement therapy